Notice Pursuant to Section 708A(5)(e) of the Corporations Act 2001

Imagion Biosystems gives notice that, on 27 August 2020 the Company issued 6,080,000 fully paid ordinary shares (Shares) in the Company as the result of…


IBX Secures Additional Capital — Shareholders Exercise Options

Imagion Biosystems announce that it has received $122k for the exercise of 4,080,000 listed options exercisable at 3 cents expiring on 28 April 2023. In…


Appendix 3G

The attached ASX announcement in relation to IBX Appendix 3G was released to market. Read the announcement.


Appendix 4D and Half Year Results H1 2020

Imagion Biosystems has announced Appendix 4D and Half Year Results H1 2020. These are the highlights: Significant advancements towards initiating…


Notice Pursuant to Section 708A(5)(e) of the Corporations Act 2001

Imagion Biosystems Limited gives notice that, on 18 August 2020 the Company issued 21,633,200 fully paid ordinary shares (Shares) in the Company as the…


IBX Secures Additional Capital — Shareholders Exercise Options

Imagion Biosystems Limited announce that it has received $1.29m for the exercise of unlisted options issued under the terms of the 2018 Rights Issue…


Change of Director's Interest Notices

Imagion Biosystems has announced the following Change of Director's Interest Notices. Read them at ASX: Robert Proulx Michael Harsh Mark Van Asten Jovanka…


Appendix 3G — Director's Options

Imagion Biosystems has announced Appendix 3G — FY20 Director's Options. Download the announcement.


Appendix 3G — Performance Rights and Performance Options

Imagion Biosystems has announced Appendix 3G — FY20 Performance Rights and Performance Options. Download the announcement.


Phase I Study Update: Submission for Ethics Approval Filed

Imagion Biosystems is pleased to provide an update with regard to its plans to undertake a Phase I study of its first MagSense™ product for the detection of…